Company Overview of NEONC Technologies, Inc.
NEONC Technologies, Inc., a cancer biotherapy company, develops intranasal inhalation dosing therapies for the treatment of brain and lung cancers. The company was incorporated in 2008 and is based in Los Angeles, California.
10524 South La Cienega Boulevard
Los Angeles, CA 90304
Founded in 2008
Key Executives for NEONC Technologies, Inc.
Senior Vice President of Corporate Affairs
Director of Engineering & Scientific Team and Director
Compensation as of Fiscal Year 2014.
NEONC Technologies, Inc. Key Developments
NEONC Technologies, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:30 PM
Mar 12 14
NEONC Technologies, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:30 PM. Venue: New York Academy of Sciences, New York, United States.
NEONC Technologies, Inc. Announces Clinical Testing of NEO100 in Treatment of Gliomas and Other Cancers
Feb 8 13
NEONC Technologies, Inc. announced that the company's NEO100 compound will undergo extensive clinical testing for treatment of gliomas and other cancers of the central nervous system. The clinical testing program was developed at meetings in Los Angeles on January 25-26 of the company's Scientific and Clinical Advisory Board, consisting of internationally prominent researchers and clinicians in the field of neuro-oncology. Unparalleled Success in Treating Deadly Brain Cancer: Malignant gliomas currently have no cure and are nearly always fatal to patients within 12-15 months of diagnosis. Research in Brazil published in April 2010 by Dr. Clovis da Fonseca and his team, who are also founders of NEONC, in glioma patients using intranasal delivery of POH, demonstrated unparalleled success treating this disease. The study included 89 adult patients with recurrent malignant glioblastoma multiforme (GBM) and 52 matched GBM patients in a historical untreated control group. Patients with recurrent primary GBM survived significantly longer than the untreated group. Patients with primary GBM treated with inhaled POH showed a survival advantage (5.9 months) compared with the control group (2.3 months). In addition, the side effects of treatment were almost nonexistent, even in patients treated for more than four years.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries